The strong Q2 beat and accelerating U.S. launch trajectory for IMCIVREE in acquired HO validate the commercial thesis. The positive RM-718 data de-risks the pipeline and supports a potential next-generation weekly option. Watch for the Japanese PMDA decision on setmelanotide for acquired HO (expected H2 2026) and European launches (2027) as the next major catalysts. The narrowed OpEx guidance suggests improved operating discipline.
Price Chart
Executive Summary
Rhythm Pharmaceuticals reported Q2 2026 revenue of $71.3M (vs $67.7M consensus, +5.3% beat) and a GAAP EPS loss of -$0.73 (vs -$0.83 consensus, a 12.0% beat), driven by a strong U.S. launch of IMCIVREE for acquired hypothalamic obesity (HO). The company also announced positive preliminary Phase 2 data for its weekly injectable MC4R agonist RM-718, showing an -11.6% mean BMI reduction at 16 weeks, and narrowed its 2026 Non-GAAP OpEx guidance to $363M-$397M (from $385M-$415M). The combination of a top- and bottom-line beat, accelerating U.S. revenue growth (+38% QoQ), and encouraging pipeline data is a clear positive signal for the commercial story and long-term growth trajectory.
Key Financial Metrics
Key Facts
- Q2 2026 net product revenue of $71.3M, up 19% sequentially from Q1 2026 and 47% YoY.
- U.S. revenue of $51.0M (72% of total), up 38% sequentially, driven by acquired HO launch demand.
- GAAP EPS loss of -$0.73 beat consensus of -$0.83 by 12.0%.
- More than 400 patient start forms for IMCIVREE in acquired HO received from ~300 prescribers since FDA approval on March 19, 2026.
- Preliminary Phase 2 data for RM-718 showed -11.6% mean BMI reduction at 16 weeks (n=7), comparable to setmelanotide and bivamelagon.
- 2026 Non-GAAP OpEx guidance narrowed to $363M-$397M (from $385M-$415M), with R&D guidance lowered to $175M-$195M.
- Cash, cash equivalents, and short-term investments of $330.9M as of June 30, 2026, expected to fund operations for at least 24 months.
Financial Impact
Revenue beat consensus by $3.6M (+5.3%); EPS beat by $0.10 (+12.0%)
Risk Factors
- Ex-U.S. revenue declined 13% sequentially due to a $3.8M retrospective charge in France, indicating potential pricing/reimbursement headwinds in international markets.
- The company remains pre-profitable with a net loss of -$50.4M in Q2 2026, though cash runway extends at least 24 months.
- RM-718 data is preliminary (n=7 at 16 weeks); larger and longer-term data are needed to confirm durability and safety profile.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-052170 |
| Document: 0001628280-26-052170-index-headers.html | 0001628280-26-052170 |
| Document: 0001628280-26-052170-index.html | 0001628280-26-052170 |
| Document: 0001628280-26-052170.txt | 0001628280-26-052170 |
| 8-K Data (Synthetic) | 0001628280-26-052170 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 17d ago | 144 | $96.77 $99.27 | ▼ −2.58% | ▼ −0.47% | $93.68 (+3.19%) |
Aug 17, 2026 6w ago | Insider Cluster | $115.25 $113.35 | ▲ +1.65% | ▲ +1.45% | $93.68 (+18.72%) |
Aug 17, 2026 6w ago | Insider Cluster | $115.25 $113.35 | ▼ −1.65% | ▼ −1.45% | $93.68 (−18.72%) |
Aug 4, 2026 8w ago | 8-K | $105.78 $112.85 | ▲ +6.68% | ▲ +6.78% | $93.68 (−11.44%) |
Aug 4, 2026 8w ago | Press Release | $105.78 $112.85 | ▲ +6.68% | ▲ +6.78% | $93.68 (−11.44%) |
Jul 8, 2026 12w ago | Press Release | $115.48 $106.09 | ▼ −8.13% | ▼ −8.00% | $93.68 (−18.88%) |
Jun 22, 2026 14w ago | 144 | $106.19 $110.04 | ▲ +3.63% | ▲ +2.61% | $93.68 (−11.78%) |
Jun 15, 2026 15w ago | 8-K | $89.72 $106.19 | ▲ +18.36% | ▲ +20.59% | $93.68 (+4.41%) |
Jun 15, 2026 15w ago | Press Release | $89.72 $106.19 | ▲ +18.36% | ▲ +20.59% | $93.68 (+4.41%) |
Jun 13, 2026 15w ago | Press Release | $89.70 $101.39 | ▲ +13.03% | ▲ +14.42% | $93.68 (+4.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access